Sunshine Act Compliance
Sunshine Act Compliance
Search
FDA Approves Pradaxa, Marking a Major Milestone to Reduce the Risk of Stroke in Patients with Non-Valvular Atrial Fibrillation
FDA Approves Pradaxa, Marking a Major Milestone to Reduce the Risk of Stroke in Patients with Non-Valvular Atrial Fibrillation
Work Care Consortium | COVID-19 | Boehringer Ingelheim US
Click here to read more on Boehringer Ingelheim's work with the CARE Consortium in dealing with the COVID-19 pandemic.
Our goal of transforming DLL3-positive carcinomas
Our progress in developing a potential immunotherapy for DLL3-positive carcinomas.
Additional analysis of real-world data confirms sequential Gilotrif® followed by osimertinib provided a median overall survival of nearly four years in U.S.-treated patients with EGFR mutation-positive NSCLC
Additional analysis of real-world data confirms sequential Gilotrif® followed by osimertinib provided a median overall survival of nearly four years in U.S.-treated patients with EGFR mutation-positive NSCLC
Jardiance® (empagliflozin) to be studied for the treatment of people with chronic heart failure
Jardiance® (empagliflozin) to be studied for the treatment of people with chronic heart failure
Clinical Trials
Boehringer Ingelheim is committed to advancing the discovery of new medicines through clinical trials.
U.S. FDA Accepts New Drug Application for Triple Combination Tablet for Adults with Type 2 Diabetes
U.S. FDA Accepts New Drug Application for Triple Combination Tablet for Adults with Type 2 Diabetes
Achieving Health Equity: The Importance of Patient Input at Every Phase of Care
Learn more about how our BI Diversity and Inclusion Patient Council illuminates the impact of health inequities & how we can work together to be upstanders.
Patient Week 2024 demonstrates importance of #PatientPoweredProgress
Learn about how we focus on putting patients first and finding solutions to meet their healthcare needs.
Boehringer Ingelheim Partners with Express Scripts on their Patient Assurance Program Expansion for People with Type 2 Diabetes
Boehringer Ingelheim Partners with Express Scripts on their Patient Assurance Program Expansion for People with Type 2 Diabetes
Internal Teat Sealant for Dairy Cows | Boehringer Ingelheim US
Boehringer Ingelheim adds internal teat sealant to their dairy mastitis portfolio, with a more ergonomic design and improved removal process.
Boehringer Ingelheim and Lilly expand heart failure program for Jardiance with new exercise capacity trials
Boehringer Ingelheim and Lilly expand heart failure program for Jardiance with new exercise capacity trials
ATS Announces that BI is First Donor of COVID-19 Fund | Boehringer Ingelheim US
American Thoracic Society Announces that Boehringer Ingelheim is the first donor of its COVID‐19 Crisis Fund
Boehringer Ingelheim Enters Global Licensing Agreement to Develop and Commercialize Innovative Antibodies from A*star for Targeted Cancer Therapies
Boehringer Ingelheim Enters Global Licensing Agreement to Develop and Commercialize Innovative Antibodies from A*star for Targeted Cancer Therapies
PI Update for Pradaxa® (dabigatran etexilate) | BI US
Read more about three important announcements regarding the US prescribing information of the oral anticoagulant (OAC) PRADAXA, for patients with NVAF.
Bigger Role in Ensuring Food Security | Boehringer Ingelheim US
As the population of the earth grows, animal health becomes fundamental in ensuring well-being and the global protein supply. Click here to find out more.
Overcoming stigma and advancing lung cancer advocacy
As part of Big Little Things, we teamed up with top patient representatives from around the world to answer the most searched questions about lung cancer.
Patients with a rare and aggressive form of liposarcoma need treatment advances
Patients with a rare and aggressive form of liposarcoma need treatment advances
New agreement with Quallent expands biosimilar access
Boehringer Ingelheim enters private label agreement for biosimilar
Data Show Safety of Pradaxa® (dabigatran etexilate) in Children | Boehringer Ingelheim US
BI announces results from 2 pediatric studies of PRADAXA, presented at the ISTH Congress in Melbourne. View ISI, PI and Med Guide.
New Study Results Published in the New England Journal of Medicine Show Dabigatran Etexilate Mesylate Reduces the Risk of Recurrent Venous Thromboembolism
New Study Results Published in the New England Journal of Medicine Show Dabigatran Etexilate Mesylate Reduces the Risk of Recurrent Venous Thromboembolism
Boehringer Ingelheim Advances Novel Bi-specific TRAILR2/CDH17 Antibody to Phase 1 Clinical Trial for Patients Living with Gastrointestinal Cancers
Boehringer Ingelheim Advances Novel Bi-specific TRAILR2/CDH17 Antibody to Phase 1 Clinical Trial for Patients Living with Gastrointestinal Cancers
FDA approves Gilotrif® (afatinib) in EGFR NSCLC | Boehringer Ingelheim US
FDA announces approval of a supplemental sNDA for GILOTRIF for the treatment of patients with metastatic NSCLC. View ISI, PI and Med Guide.
Confronting health disparities in clinical trials
As a research-driven pharmaceutical company, one of our priorities is to ensure there’s more representation from underserved communities, particularly for clinical cancer trials.